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THROMBOSIS AND HEMOSTASIS
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factor genes on plasma factor VIII activity: the ARIC Study
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Factor VIII (FVIII) functions as a cofactor
for factor IXa in the contact coagulation
pathway and circulates in a protective com-
plex with von Willebrand factor (VWF).
Plasma FVIII activity is strongly influenced
by environmental and genetic factors
through VWF-dependent and -independent
mechanisms. Single nucleotide polymor-
phisms (SNPs) of the coding and promoter
sequence in the FVIII gene have been exten-
sively studied for effects on FVIII synthesis,
secretion, and activity, but impacts of non–
disease-causing intronic SNPs remain
largely unknown. We analyzed FVIII SNPs
and FVIII activity in 10 434 healthy Ameri-
cans of European (EA) or African (AA) de-
scent in theAtherosclerosis Risk in Commu-
nities (ARIC) study. Among covariates, age,
race, diabetes, and ABO contributed 2.2%,
3.5%, 4%, and 10.7% to FVIII intersubject
variation, respectively. Four intronic FVIII
SNPsassociatedwithFVIII activityand8with
FVIII-VWF ratio in a sex- and race-dependent
manner. The FVIII haplotypes AT and
GCTTTT also associated with FVIII activity.
Seven VWF SNPs were associated with FVIII
activity in EA subjects, but no FVIII SNPs
were associated with VWF Ag. These data
demonstrate that intronic SNPs could di-
rectly or indirectly influence intersubject
variation of FVIII activity. Further investiga-
tion may reveal novel mechanisms of regu-
lating FVIII expression and activity. (Blood.
2012;119(8):1929-1934)
Introduction
Factor VIII (FVIII) functions as a cofactor for factor IXa in the contact
coagulation pathway and is synthesized as a single-chain precursor with
a domain structure of n-A1-A2-B-A3-C1-C2-c.1,2 It is secreted as a
noncovalent heterodimer produced from intracellular cleavage at 2 pep-
tide bonds in the B domain: Arg1313-Ala1314 and Arg1648-Glu1649,
generating a heavy (A1, A2, and a part of B domains) and a light chain
(A3, C1, and C2 domains).2,3 FVIII is synthesized in multiple cell types,
but hepatic sinusoidal endothelial cells appear to be a major source of
circulating FVIII.4,5 FVIII is highly sensitive to proteolysis and is
protected by forming a high-affinity complex (Kd 0.2-0.5nM) with
VWF in the circulation.6,7 The half-life of VWF-bound FVIII is
significantly longer than plasma FVIII from patients lacking VWF (type
III VWD).8,9 This FVIII-VWF complex is formed primarily through an
interaction between the light chain of FVIII7,10 and the D and D3
domains of VWF.11-13 FVIII is activated to FVIIIa when it is cleaved by
thrombin at A1-A2 and A2-B junctions in the heavy chain and in the
N-terminal region of the light chain,3 whereas cleavage in the light chain
releases FVIIIa from VWF.14
The molar ratio of circulating FVIII and VWF is  1:50 of
FVIII to VWF monomer.6 However, the 2 molecules can form a
complex in a 1:1 stoichiometry in vitro, suggesting that all
FVIII-binding sites on a VWF multimer are available and the
FVIII-VWF ratio may primarily depend on the amount of circulat-
ing FVIII.6,7 The baseline level of FVIII varies considerably among
individuals and increase further in conditions such as inflamma-
tion.15 This variation is caused by multiple factors, but genetic influence
is significant. One major genetic factor is ABO blood types,16,17 which
affects FVIII activity primarily because of ABO impact on VWF.18
However, a small, but significant, VWF-independent ABO effect on
FVIII is also reported in healthy subjects.19
The FVIII gene spans 186 kb on chromosome X (q28) and contains
26 exons that range from 69 bp to 3.1 kb in size.20,21 FVIII introns vary
from 0.2 kb for intron 17 to 32 kb for intron 22. Within intron 22, there
are 2 distinct non-FVIII gene elements controlled by a bidirectional
promoter.22,23 The FVIII mRNA is  9 kb that encodes a mature
glycoprotein of 2332 aa without known alternatively spliced forms.2
The FVIII locus is polymorphic with a majority of single nucleotide
polymorphisms (SNPs) located in introns,24,25 but impacts of these
intronic and non–disease-causing SNPs on plasma FVIII activity remain
largely unknown. In this study, we correlated 19 FVIII SNPs with FVIII
activity measured in plasma samples from 10 434 healthy American
subjects of European (EA, 8056) or African descent (AA, 2378) in the
Atherosclerosis Risk in Communities (ARIC) Study. In addition,
75 VWF SNPs that we have previously studied for their impact on VWF
Ag26 were also analyzed for their effect on FVIII activity.
Methods
Study population
ARIC is a prospective cohort study designed to assess atherosclerosis,
clinical atherosclerotic diseases, and cardiovascular risk factors. Baseline
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samples and demographic data were collected from 15 792 subjects of 45 to
64 years of age using probability sampling from Forsyth County, NC;
Jackson, MS; the northwestern suburbs of Minneapolis, MN; and Washing-
ton County, MD from 1987 to 1989 (http://www.cscc.unc.edu/aric/). This
study included Americans of EA and AA descent. Subjects who did not
consent to share genetic information were excluded from the study (N 45).
The use of these data were approved by the institutional review boards of all
participating institutions for the ARIC study.
Baseline measurements
Blood was drawn from an antecubital vein from subjects who were asked to
arrive at clinic after fasting at least 12 hours. FVIII activity was measured
by the ability of a testing sample to correct clotting time of human
FVIII-deficient plasma and reported as a percentage (George King Biomedi-
cal Inc).27 VWF Ag was determined by a commercial ELISA kit (American
Bioproducts) and reported as a percentage of the Universal Coagulation
Reference Plasma (Thromboscreen, Pacific Hemostasis; Curtin Matheson
Scientific Inc). The reliability coefficient (1  intraindividual variance/total
variance) obtained from repeat testing of individuals over several weeks
was 0.68 for VWF and 0.86 for FVIII. Age, race, sex, body mass index
(BMI), hypertension, diabetes, ever smoking status, and ABO genotype
were adjusted for their known impacts on VWF and FVIII.27,28
SNP genotyping and haplotype construction
SNPs genotyped on an Affymetrix 6.0 platform in the region encompassing
the FVIII gene (153 717 264 to 153 904 192 on X chromosome) and VWF
gene (5 928 997-6 098 180 on chromosome 12) were included in the data
analyses. A total of 19 FVIII and 75 VWF SNPs were analyzed for the study
(supplemental Table 1, available on the Blood Web site; see the Supplemen-
tal Materials link at the top of the online article), where letters A and B
indicate major and minor alleles. We also used the fastPHASE 1.2 program
to resolve haplotypes from the unphased SNP genotype data and Haploview
to determine regions in strong linkage disequilibrium (LD), their cosegrega-
tion rates, and underlying haplotypes in each region.26,29
Because of known associations between O blood type and plasma VWF
levels and FVIII activity, blood type O was genotyped based on a single
base deletion (G) at nt 261 (RS8176719) that shifts the reading frame to
generate a premature termination codon. The truncated enzyme is unable to
transfer a sugar moiety to the H Ag. This SNP was therefore used to
distinguish between type O (homozygous for nt261) and type non-O
subjects in the analysis (nt261 was on one allele or absent).30
Data analysis
All SNPs were evaluated for Hardy-Weinberg Equilibrium (HWE) by
2 test statistics or exact tests, as appropriate. HWE was tested for each
race-by-sex level separately. The majority of FVIII SNPs were in HWE for
EA women except RS5987068 and RS5987061, which did not have enough
variation to test HWEs, and RS12392769, which was not in HWE for AA
women. Because the FVIII gene is on the X chromosome, tests of HWE
were irrelevant for men. Statistical significance was determined at the level
of P  .0005 using a Bonferroni adjustment for multiple comparisons,
which was calculated based on a formula of 0.05 divided by a total of
94 SNPs included in analysis.
Linear models were used to evaluate the association of FVIII activity
with each FVIII SNP. The analysis was stratified on race and sex. The
models were adjusted for age, hypertension, diabetes, BMI, ever smoking,
and ABO. For haplotype analyses at each block of interest, a numerical
variable was assigned for each common haplotype by counting the
frequency (0, 1, or 2) of the haplotype for women, but there are only
2 possible levels of the haplotype variable (0 or 1) for men because the
FVIII gene is on the X chromosome. Linear models were also used to assess
the association between FVIII or VWF plasma levels and haplotype
frequencies.
Results
Among the 15 792 ARIC participants of EA and AA descent,
10 434 were included in the analyses after exclusion of subjects for
lacking data on (1) FVIII activity, VWF Ag, or both (n 280); (2)
SNPs on both genes (n 3032); or (3) ABO genotypes (n 1898).
Demographics for the 10 434 subjects are displayed in supplemental
Table 2. There were significant differences in age, BMI, and
smoking status between the 4 race-by-sex groups. EA subjects were
older and have a lower BMI, compared with AA subjects, for both
sexes. More men were in ever-smoking status than women were for
both races. AA subjects had higher prevalences of diabetes and
hypertension compared with EA subjects.
FVIII activity and association with VWF Ag levels
The mean plasma FVIII activity and VWF Ag levels were 127.5%
(SD  37.3 and median at 123%) and 113.5% (SD  45.2 and
median at 106%), respectively. Both mean values were 100% for
reasons to be further determined. One possibility is the inclusion of
a large number of AA subjects who are known to have higher FVIII
and VWF. Both measurements varied considerably among the
cohort subjects (20%-540% for FVIII and 22%-412% for VWF,
Figure 1). The FVIII-VWF ratio ranged from 0.18 to 3.73 with a
mean ratio of 1.20. The correlation coefficient between FVIII
activity and VWF Ag were 0.70 (women) and 0.69 (men) for EA
subjects and 0.69 (women) and 0.74 (men) for AA subjects,
respectively. FVIII activity and VWF Ag were significantly differ-
ent among the 4 race-by-sex groups. FVIII activity was higher for
women, compared with men (for both race), and for AA subjects,
compared with EA subjects. AA subjects also had a higher VWF
Ag, compared with EA subjects. The FVIII/VWF ratio was higher
in women, compared with men, but was comparable between the
race groups (Table 1). When both measurements were grouped in
Figure 1. Distributions of FVIII activity, VWF Ag, and FVIII-VWF ratio in 10 434 subjects included in the study.
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quartiles, FVIII activity was found in parallel with VWF Ag in 39%
to 66% of subjects, whereas up to 27% mismatched. Among these
mismatched, 2% of subjects had a significant split where a very
high VWF Ag (fourth quartile) was paired with a very low FVIII
activity (first quartile) or vice versa (Table 2). This split between
the 2 measurements varied from 1% to 3% in the 4 race-by-sex
groups (supplemental Table 3).
There were 5005 subjects (48%) who are the O blood type and
5429 subjects (52%) who are non-O blood type. ABO genotype
accounted for 10.7% of FVIII variation when it was analyzed
together with nongenetic covariates in a linear model (supplemen-
tal Table 4). Among the nongenetic covariates used for adjustment,
race, diabetes, and age accounted for 4.0%, 3.5%, and 2.2% of the
variance, respectively.
SNP and haplotype correlation with FVIII activity
There were 19 FVIII SNPs available in the ARIC genome-wide
association study (GWAS) database. Eighteen of them were
intronic (94.7%) and 1 was nonsynonymous from exon 26
(RS1800297) that changes a methionine residue at the position of
2257 to a valine residue (M2257V). Seventy-five VWF SNPs were
also analyzed for their effect on FVIII activity. Among them,
70 were intronic (93.3%) and 5 exonic (6.7%), but all coding SNPs
were synonymous.26 Among the 19 FVIII SNPs, RS6643714 was
significantly associated with FVIII activity after adjustment for
age, sex, smoking status, diabetes, and hypertension. A further
adjustment with ABO yielded 3 additional SNPs that were signifi-
cantly associated with FVIII activity (Table 3). The association of
these 4 SNPs with FVIII activity was found in EA men, but not in
EA women and AA subjects of either sex. All 4 SNPs were also
associated with the FVIII-VWF ratio, but again in EA men only
(Table 4). In addition, 4 new SNPs were associated with the
FVIII-VWF ratio in EA subjects of either sex, but not in AA
subjects.
The large ARIC database allowed us to construct FVIII
haplotypes that included rare alleles to identify specific SNPs that
are transmitted together and to determine whether their effects are
additive. Using the fastPHASE 1.2 program, we identified 2 major
haplotype blocks that are in linkage disequilibrium in the FVIII
gene and accounted for 82.4%, 73.5%, 83.6%, and 74.3% of all
haplotypes for EA women, AA women, EA men, and AA men,
respectively (Figure 2). SNPs in each LD haplotype were identical
for male and female subjects, but varied significantly between AA
and EA subjects (Table 5), indicating a highly diverse coaggrega-
tion of SNPs between EA and AA subjects. Among the haplotypes,
AT in block 1 and GCTTTT in block 2 were associated with FVIII
activity in EA men after adjustment for age, BMI, ever smoking,
diabetes, hypertension, and ABO (Table 6).
Cross-genetic influence between FVIII and VWF SNPs
Finally, we examined cross-influence between the 2 measurements
and found no FVIII SNPs associated with VWF Ag levels before or
after adjustment for ABO and other covariates. In contrast, 5 and
2 VWF SNPs were associated with FVIII activity for EA women
and EA men, respectively (Table 7), but not for AA subjects.
Table 1. Mean (SD) of FVIII activity and VWF Ag by race and sex (N  10 434)
Characteristic Total EA women, N  4282 EA men, N  3774 AA women, N  1505 AA men, N  873 P*
Factor VIII (%) 127.59 (37.32) 125.51 (34.05) 121.13 (33.19) 144.49 (46.31) 135.44 (41.84)  1  1031
VWF (%) 113.53 (45.15) 108.44 (41.10) 111.34 (42.36) 128.15 (54.42) 122.74 (51.16)  1  1031
FVIII-VWF ratio† 1.20 (0.31) 1.23 (0.32) 1.16 (0.30) 1.22 (0.35) 1.18 (0.30) 4.27  1025
EA indicates Americans of European descent; and AA, Americans of African descent.
*ANOVA.
†One subject was excluded from the statistics for the ratio because he was considered to be an outlier with a ratio of 6.13 ( 15  SD).
Table 2. Quartile of VWF Ag by quartile of FVIII activity (N  10 434)
VWF
Quartile 1st (%) 2nd (%) 3rd (%) 4th (%) Total (%)
FVIII, 1st 1753 (66) 642 (24) 194 (8) 56 (2) 2645 (25)
FVIII, 2nd 678 (26) 1071 (41) 692 (27) 214 (8) 2655 (25)
FVIII, 3rd 183 (7) 705 (27) 1001 (39) 704 (27) 2593 (25)
FVIII, 4th 42 (2) 217 (8) 692 (27) 1590 (62) 2541 (24)
Table 3. Adjusted mean of FVIII activity (%) by FVIII genotype for EA males (N  3774)
SNP* Location ABO adjusted†
FVIII activity (%)
PAA BB
RS5945122 Intron13 No 121.69 (0.57) 117.35 (1.34) 2.9  103
Yes 121.77 (0.54) 116.88 (1.27) 3.9  104
RS6643714‡ Intron14 No 122.51 (0.66) 118.50 (0.86) 2.2  104
Yes 122.52 (0.63) 118.49 (0.81) 8.8  105
RS7061362‡ Intron11 No 121.70 (0.57) 117.29 (1.34) 2.5  103
Yes 121.78 (0.54) 116.82 (1.27) 3.2  104
RS5945258‡ Intron11 No 121.70 (0.57) 117.24 (1.34) 2.2  103
Yes 121.78 (0.54) 116.80 (1.26) 3  104
All models adjusted for age, BMI, diabetes, hypertension, and smoking status.
EA indicates Americans of European descent.
*RS5986899, RS5987057, RS5987068, RS5987073, RS7056252, RS12014480, RS1800297, RS5987056, RS5987061, RS7357998, and RS12392769 were too sparse
to be analyzed for EA men.
†Participants with “-G” at RS8176719 and “GT” at RS8176746 were excluded from the ABO genotype definition (N  1284) and those with no information on RS8176719
or RS8176746 were also excluded (N  614).
‡Due to small counts, AB genotype was combined with minor (BB) genotype.
CORRELATION OF FACTOR VIII SNP WITH ACTIVITY 1931BLOOD, 23 FEBRUARY 2012  VOLUME 119, NUMBER 8
For personal use only.on January 19, 2018. by guest  www.bloodjournal.orgFrom 
Discussion
Using the ARIC database, we analyzed 19 FVIII SNPs and
haplotypes for their association with FVIII activity and FVIII-
VWF ratio. We also examined a cross-genetic influence of VWF
SNPs that we have recently studied26 on FVIII activity. Consistent
with a previous report,27 FVIII activity varied significantly among
subjects (Figure 1) and was higher in AA subjects than EA subjects,
but the FVIII-VWF ratio was comparable between the 2 ethnic
groups (Table 1). This difference may be in part attributed to a
higher BMI and increased prevalence of diabetes and hypertension
in AA subjects (supplemental Figure 2A) because these covariates
are known to associate with inflammation, a condition that
increases secretion of acute-phase reactants such as FVIII and
VWF. Women had significantly higher FVIII activity and a greater
FVIII-VWF ratio compared with men. Age, race, and diabetes had
the strongest influence on variations of FVIII activity, whereas the
influence of BMI and sex was smaller, but significant (supplemen-
tal Figure 4). ABO (defined as O type vs non-O type) accounted for
10.7% of FVIII variation when it was analyzed together with
environmental covariates in a single linear model. This study has
also made 3 novel findings.
First, it has been reported that FVIII varies with VWF to keep its
ratio relatively constant over a wide range of VWF levels.24 When
analyzed in quartiles, we did find that 39%-66% of subjects had
FVIII activities in parallel with VWF levels (Figure 2). However,
this parallel distribution between the 2 measurements was not
detected in up to 61% of subjects. Among them, 2% subjects had
either a very high VWF level paired with a very low FVIII or a very
high FVIII paired with a very low VWF. This extreme split was
consistently observed (1%-3%) when data were analyzed by race
and sex (supplemental Figure 3), suggesting that FVIII and VWF
ratio varies among individuals considerably more than previously
reported. This extreme split may be explained by variable rates of
synthesis of the 2 factors, different association kinetics between
FVIII, and assay variations. Whether VWF multimer size and
conformation affect its association with FVIII is not known. This
split may be physiologically significant because the FVIII-VWF
ratio is used to distinguish accelerated VWF clearance found in a
subset of patients with VWD.31
Second, we identified 4 FVIII SNPs that were significantly
associated with FVIII activity after adjustment for age, sex, BMI,
smoking status, diabetes, hypertension, and ABO genotypes (Table
3). These positive SNPs are intronic and clustered in intron 11, 13,
and 14 that flank exons encoding A2 and B domains of the FVIII
Table 4. Statistical significance of association of FVIII SNPs with the





(men, N  3774)*
P
(women, N  4282)†
RS4898352 No 5.2  106 3.1  106
Yes 2.8  106 4.6  106
RS5987077 No 1.2  105 5.6  106
Yes 6.1  106 7.2  106
RS1470586 No 1.2  106 8.2  106
Yes 8.5  107 1.3  105
RS6643622 No 4.7  105 1.1  105
Yes 2.3  105 1.7  105
RS5945122‡ No 2.1  104 4.9  104
Yes 3.8  104 5  104
RS5945258‡ No 1.7  104 5.6  104
Yes 2.9  104 5.7  104
RS6643714‡ No 2.2  107 8.9  104
Yes 1.5  107 1  104
RS7061362‡ No 2  104 5.1  104
Yes 3.7  104 5.1  104
Models are adjusted for age, BMI, ever smoking, diabetes, and hypertension
(1 subject with outlier was not included from these models).
SNP indicates single nucleotide polymorphism; and EA, Americans of European
descent.
*There were 37 men were missing information on at least 1 of the predictors and
were excluded from these models.
†There were 27 women were missing information on at least 1 of the predictors
and were excluded from these models.
‡These SNPs were associated with FVIII activity in EA males as individual and in
haplotypes.
Figure 2. Haplotypes constructed from 19 available FVIII SNPs in a cohort of
10 434 subjects.
Table 5. Haplotype blocks for FVIII SNPs
AA subject EA subject
Block 1 Block 2 Block 1 Block 2
rs4898352 rs5987077 rs4898352 rs6643622







SNP indicates single nucleotide polymorphism; AA, Americans of African de-
scent; and EA, Americans of European descent.
*SNPs that are individually associated with FVIII activity in EA subjects asindi-
cated in Table 3.
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heavy chain.24 The effect sizes of these intronic SNPs are smaller,
but often additive. Interestingly, these SNPs were found to
associate with FVIII activity only in EA men, even though they
were also detected in EA women and AA subjects. These 4 positive
SNPs were also associated with the FVIII-VWF ratio in EA men
and 4 additional SNPs were associated with the ratio in EA men and
women. In addition, 2 major haplotype boxes were identified from
these 19 SNPs and counted for 73.5%-83.6% of all FVIII gene
haplotypes (Figure 2). SNPs included in the 2 haplotype boxes
were significantly different between EA and AA subjects (Table 5).
The haplotype TC in box 1 and haplotype GCTTTT in box 2 were
associated with FVIII activity after adjustment for environmental
covariates and ABO, but only in EA men (Figure 6). Together, these
data suggest that intronic SNPs in the FVIII gene could affect FVIII
activity, potentially by affecting gene splicing and/or mRNA
stability, especially those at or near a splice site, or serving as a
marker for remote variations. For the former, Bagnall et al reported
an intronic mutation that creates a new donor splice site in intron
1 and is believed to be responsible for developing hemophilia A.32
For the latter, several SNPs outside of the FVIII gene are found to
associate with FVIII activity in a recent GWAS by the Cohorts for
Heart and Aging Research in Genomic Epidemiology (CHARGE)
Consortium.33 Our analyses reveal a striking sex and race disparity
in SNP association that has not been previously reported and its
cause remains unknown. The finding that more SNPs were
associated with the FVIII-VWF ratio than with FVIII activity
would suggest that VWF levels may contribute to this disparity.
The FVIII gene location to the X chromosome may also contribute
to a sex-dependent association. As shown in Table 1, men had
 5% less plasma FVIII activity than women, even though they
have only one X chromosome, suggesting the presence of genetic
or environmental modifiers to regulate rates of FVIII synthesis,
secretion, and/or clearance in a sex-specific manner. Alternatively,
this disparity may be attributable to an insufficient sample size to
detect subtle differences associated with intronic SNPs for AA
subjects. However, this is less likely because frequencies of minor
genotypes in AA subjects were actually significantly higher than
EA subjects (supplemental Table 1A).
Third, we have identified 5 and 2 VWF SNPs that associated
with FVIII activity in EA women and men, respectively, after
adjustment for covariates and ABO (Table 6). The association was
only found in EA subjects, but differentially distributed between
EA men and EA women. Furthermore, all these associative VWF
SNPs, except RS723190, were previously associated with VWF Ag
levels in the ARIC cohort.26 RS1063857, which results in a
synonymous amino acid substitution at position 795 of VWF, was
associated with VWF Ag and FVIII activity in a recent GWAS
study.33 Whether the association is sex or race specific was not
determined in these studies. In contrast, no FVIII SNPs were
associated with VWF levels, suggesting that VWF determines
this cross-genetic influence primarily because of its function as a
FVIII carrier.
Table 7. Adjusted mean of FVIII activity (%) by VWF SNPs
VWF SNP ABO adjusted
FVIII activity for VWF genotype, mean (SEM)
PAA AB BB
EA women, N  4282*†§
RS216315 No 126.50 (0.54) 120.66 (1.22) 117.91 (5.02) 2.4  105
Yes 126.53 (0.51) 120.53 (1.14) 117.88 (4.69) 2.7  106
RS216318 No 126.51 (0.54) 120.66 (1.22) 117.87 (4.90) 2.2  105
Yes 126.54 (0.51) 120.51 (1.14) 117.89 (4.58) 2.3  106
RS216299 No 126.30 (0.55) 121.67 (1.20) 121.81 (4.46) 1.5  103
Yes 126.42 (0.51) 121.19 (1.12) 120.51 (4.17) 6.2  105
RS216295 No 126.34 (0.55) 121.70 (1.21) 119.86 (4.92) 1.1  103
Yes 126.42 (0.51) 121.36 (1.13) 118.76 (4.59) 8  105
RS216298 No 126.32 (0.54) 121.61 (1.21) 119.77 (4.80) 8.7  104
Yes 126.43 (0.51) 121.15 (1.13) 118.81 (4.48) 3.6  105
EA men, N  3774*†
RS1063857 No 118.24 (0.83) 122.25 (0.77) 125.11 (1.45) 1.9  105
Yes 118.50 (0.78) 122.11 (0.73) 124.81 (1.38) 4.3  105
RS723190‡§ No 120.42 (0.56) 125.67 (1.57) 1.6  103
Yes 120.36 (0.53) 126.13 (1.48) 2.5  104
SNP indicates single nucleotide polymorphism; and EA, Americans of European descent.
*All means were adjusted for age, sex, BMI, diabetes, hypertension, and ever-smoking status.
†RS7968035, RS2239143, RS16932374, and RS3213721 were too sparse to analyze for both EA women and men.
‡Due to small counts, AB genotype was combined with the minor BB genotype.
§All SNPs except RS723190 were previously associated with VWF Ag.31
Table 6. Difference (and P value) in adjusted mean FVIII activity (%)
by copy numbers of the haplotype and by ABO adjustment for EA
men (N  3671)
Haplotype ABO adjusted P Difference
Block 1*
AT No 6  104 3.74
Yes 2  104 3.89
TC No 7.7  103 3.20
Yes 7.3  103 3.05
AC No 8  102 2.95
Yes 2.9  102 3.50
Block 2*
TACCAC No 9.5  103 2.96
Yes 1.2  102 2.71
GCTTTT No 1.5  103 4.71
Yes 2  104† 5.24
GACCTT No 7.9  101 0.50
Yes 9.5  101 0.12
GACCAC No 9.2  101 0.25
Yes 6.5  101 1.11
GACCTC No 9.8  101 0.07
Yes 8.2  101 0.79
EA indicates Americans of European descent.
*Adjusted for age, BMI, diabetes, hypertension, and ever smoking.
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In summary, we have found considerable variation in FVIII activity
and FVIII-VWF ratios among the ARIC subjects. Four and 8 FVIII
SNPs from a pool of 19 were associated with FVIII activity and
FVIII-VWF ratio, respectively. We also identified 2 major haplotype
blocks associated with FVIII activity. Strikingly, these associations were
primarily found EA men, with some in EA female, but none in AA
subjects. The impact of sex and race on FVIII activity remains to be
further investigated. The results suggest that these intronic SNPs could
directly regulate FVIII expression or act as markers for its regulation.
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